Adcendo ApS Announces First Patient Dosed in Phase I/ II ADCElerate1 Trial of ADCE-D01

Adcendo Denmark Massachusetts New York

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypesor follow the company on LinkedIn.

Logo - https://mma.prnewswire.com/media/2565778/Adcendo_Logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/adcendo-aps-announces-first-patient-dosed-in-phase-iii-adcelerate1-trial-of-adce-d01-302475077.html